Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
GSK starts 2020 on a high, but warns of tougher times aheadGlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving Share XGSK starts 2020 on a high, but warns of tougher times aheadhttps://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
FDA approval gained, Glaxo awaits key committee blessing for ShingrixThe FDA granted approval to GSK’s new shingles vaccine Shingrix on Friday, giving the company the green light Share XFDA approval gained, Glaxo awaits key committee blessing for Shingrixhttps://pharmaphorum.com/news/shingrix-approved-glaxo-awaits-cdc-decision/
Tipped to hit $1bn, GSK’s Shingrix gains committee approvalGlaxoSmithKline’s shingles vaccine Shingrix has gained the unanimous backing of an FDA advisory committee. The Vaccines and Related Share XTipped to hit $1bn, GSK’s Shingrix gains committee approvalhttps://pharmaphorum.com/news/tipped-hit-1bn-gsks-shingrix-gains-committee-approval/
